BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007;196 Suppl 1:S52-62. [PMID: 17624827 DOI: 10.1086/518662] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Santana CA, Gutierrez EB. Evaluation of the Dispensing Rate of Isoniazid Used in the Preventive Treatment of Tuberculosis in a Service Specialized in HIV / AIDS. Revista Científica Multidisciplinar Núcleo do Conhecimento 2021. [DOI: 10.32749/nucleodoconhecimento.com.br/health/isoniazid-used] [Reference Citation Analysis]
2 Santana CA, Gutierrez EB. Avaliação Da Taxa De Dispensação De Isoniazida Utilizada No Tratamento Preventivo De Tuberculose Em Serviço Especializado Em HIV/Aids. Revista Científica Multidisciplinar Núcleo do Conhecimento 2021. [DOI: 10.32749/nucleodoconhecimento.com.br/saude/isoniazida-utilizada] [Reference Citation Analysis]
3 Santana CA, Santos GAAD. Avaliação de hepatotoxicidade em idosos com HIV/AIDS em uso de isoniazida. Revista Científica Multidisciplinar Núcleo do Conhecimento 2020. [DOI: 10.32749/nucleodoconhecimento.com.br/saude/hepatotoxicidade] [Reference Citation Analysis]
4 Santana CA, Santos GAAD. Evaluation of hepatotoxicity in elderly with HIV/AIDS using isoniazid. Revista Científica Multidisciplinar Núcleo do Conhecimento 2020. [DOI: 10.32749/nucleodoconhecimento.com.br/health/hepatotoxicity] [Reference Citation Analysis]
5 Mandal S, Bhatia V, Sharma M, Mandal PP, Arinaminpathy N. The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach. BMC Med 2020;18:163. [PMID: 32684164 DOI: 10.1186/s12916-020-01651-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
6 Chachlioutaki K, Tzimtzimis EK, Tzetzis D, Chang MW, Ahmad Z, Karavasili C, Fatouros DG. Electrospun Orodispersible Films of Isoniazid for Pediatric Tuberculosis Treatment. Pharmaceutics 2020;12:E470. [PMID: 32455717 DOI: 10.3390/pharmaceutics12050470] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
7 Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat 2020;2020:7025738. [PMID: 32411454 DOI: 10.1155/2020/7025738] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
9 Wickremsinhe MN, Little MO, Carter AS, Sullivan KA, Lyerly AD. Beyond "Vessels and Vectors": A Global Review of Registered HIV-Related Clinical Trials with Pregnant Women. J Womens Health (Larchmt) 2019;28:93-9. [PMID: 30124366 DOI: 10.1089/jwh.2017.6857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
10 Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis 2017;21:537-43. [PMID: 28399969 DOI: 10.5588/ijtld.16.0775] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
11 Hirsch-Moverman Y, Howard AA, Frederix K, Lebelo L, Hesseling A, Nachman S, Mantell JE, Lekhela T, Maama LB, El-Sadr WM. The PREVENT study to evaluate the effectiveness and acceptability of a community-based intervention to prevent childhood tuberculosis in Lesotho: study protocol for a cluster randomized controlled trial. Trials 2017;18:552. [PMID: 29157275 DOI: 10.1186/s13063-017-2184-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
12 Karo B, Krause G, Castell S, Kollan C, Hamouda O, Haas W; ClinSurv HIV Study Group. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. BMC Infect Dis 2017;17:517. [PMID: 28743248 DOI: 10.1186/s12879-017-2627-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
13 Little MO, Lyerly AD, Mastroianni AC, Faden RR. Ethics and Research with Pregnant Women: Lessons from HIV/AIDS. In: Baylis F, Ballantyne A, editors. Clinical Research Involving Pregnant Women. Cham: Springer International Publishing; 2016. pp. 227-46. [DOI: 10.1007/978-3-319-26512-4_13] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Krubiner CB, Faden RR, Cadigan RJ, Gilbert SZ, Henry LM, Little MO, Mastroianni AC, Namey EE, Sullivan KA, Lyerly AD. Advancing HIV research with pregnant women: navigating challenges and opportunities. AIDS 2016;30:2261-5. [PMID: 27490637 DOI: 10.1097/QAD.0000000000001214] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
15 Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S. Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010. Trans R Soc Trop Med Hyg 2015;109:653-9. [PMID: 26385936 DOI: 10.1093/trstmh/trv074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One 2015;10:e0137492. [PMID: 26348618 DOI: 10.1371/journal.pone.0137492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
17 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
18 Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health 2015;15:346. [PMID: 25886730 DOI: 10.1186/s12889-015-1719-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
19 Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med 2014;5:a017798. [PMID: 25359550 DOI: 10.1101/cshperspect.a017798] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 11.6] [Reference Citation Analysis]
20 Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J 2014;17:26. [PMID: 24932337 DOI: 10.11604/pamj.2014.17.26.2641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
21 Gomes VF, Andersen A, Lemvik G, Wejse C, Oliveira I, Vieira FJ, Carlos LJ, Vieira Cda S, Aaby P, Gustafson P. Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study. BMJ Open 2013;3:e001545. [PMID: 23535699 DOI: 10.1136/bmjopen-2012-001545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
22 Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011;134:850-65. [PMID: 22310818 DOI: 10.4103/0971-5916.92630] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 5.5] [Reference Citation Analysis]
23 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
24 Al Jumaah S. Tuberculosis. Textbook of Clinical Pediatrics 2012. [DOI: 10.1007/978-3-642-02202-9_95] [Reference Citation Analysis]
25 Saraceni V, Pacheco AG, Golub JE, Vellozo V, King BS, Cavalcante SC, Eldred L, Chaisson RE, Durovni B. Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil. Braz J Infect Dis 2011;15:249-52. [PMID: 21670926 DOI: 10.1016/s1413-8670(11)70184-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
26 Moura LC, Ximenes RA, Ramos HL, Miranda Filho DB, Freitas CD, Silva RM, Coimbra I, Batista Jd, Montarroyos UR, Militão Albuquerque Mde F. An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS. BMC Public Health 2011;11:687. [PMID: 21892936 DOI: 10.1186/1471-2458-11-687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Venkatesh KK, Swaminathan S, Andrews JR, Mayer KH. Tuberculosis and HIV Co-Infection: Screening and Treatment Strategies. Drugs 2011;71:1133-52. [DOI: 10.2165/11591360-000000000-00000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
28 Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One 2010;5:e15241. [PMID: 21209936 DOI: 10.1371/journal.pone.0015241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
29 Mnyani C, Mcintyre J. Tuberculosis in pregnancy: Tuberculosis in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology 2011;118:226-31. [DOI: 10.1111/j.1471-0528.2010.02771.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
30 Marais BJ, Schaaf HS. Childhood tuberculosis: an emerging and previously neglected problem. Infect Dis Clin North Am 2010;24:727-49. [PMID: 20674801 DOI: 10.1016/j.idc.2010.04.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
31 Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010;24 Suppl 5:S57-65. [PMID: 21079430 DOI: 10.1097/01.aids.0000391023.03037.1f] [Cited by in Crossref: 62] [Cited by in F6Publishing: 81] [Article Influence: 4.8] [Reference Citation Analysis]
32 Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24 Suppl 5:S5-13. [PMID: 21079429 DOI: 10.1097/01.aids.0000391010.02774.6f] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
33 Rylance J, Pai M, Lienhardt C, Garner P. Priorities for tuberculosis research: a systematic review. Lancet Infect Dis 2010;10:886-92. [PMID: 21050822 DOI: 10.1016/S1473-3099(10)70201-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
34 Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010;10:267. [PMID: 20840743 DOI: 10.1186/1471-2334-10-267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
35 Naidoo K, Naidoo K, Padayatchi N, Abdool Karim Q. HIV-Associated Tuberculosis. Clin Dev Immunol 2011;2011:585919. [PMID: 20871843 DOI: 10.1155/2011/585919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
36 Gutierrez EB, Gomes V, Picone CM, Suga H, Atomiya AN. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS. HIV Med 2009;10:564-72. [PMID: 19785665 DOI: 10.1111/j.1468-1293.2009.00730.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, El-sadr WM, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SH, Whitty CJ, Atun R, Zumla A. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. The Lancet 2010;375:2179-91. [DOI: 10.1016/s0140-6736(10)60554-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
38 Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, Harrington M, Maher D, Williams BG, De Cock KM. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010;375:1906-19. [PMID: 20488516 DOI: 10.1016/S0140-6736(10)60409-6] [Cited by in Crossref: 154] [Cited by in F6Publishing: 177] [Article Influence: 11.8] [Reference Citation Analysis]
39 Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, Machado Junior A, Lemos AC, Netto AR, Durovni B, Sant'Anna CC, Lima D, Capone D, Barreira D, Matos ED, Mello FC, David FC, Marsico G, Afiune JB, Silva JR, Jamal LF, Telles MA, Hirata MH, Dalcolmo MP, Rabahi MF, Cailleaux-Cesar M, Palaci M, Morrone N, Guerra RL, Dietze R, Miranda SS, Cavalcante SC, Nogueira SA, Nonato TS, Martire T, Galesi VM, Dettoni Vdo V; BTA Committee on Tuberculosis., BTA Guidelines on Tuberculosis Work Group. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol 2009;35:1018-48. [PMID: 19918635 DOI: 10.1590/s1806-37132009001000011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 134] [Article Influence: 7.1] [Reference Citation Analysis]
40 Dodd PJ, Millington KA, Ghani AC, Mutsvangwa J, Butterworth AE, Lalvani A, Corbett EL. Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity. Am J Epidemiol 2010;171:1037-45. [PMID: 20382638 DOI: 10.1093/aje/kwq017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
41 Grange J, Mwaba P, Dheda K, Höelscher M, Zumla A. World TB Day 2010 - New innovations are required for enhancing the global fight against Tuberculosis: the ‘Captain of all these men of death’. Tropical Medicine & International Health 2010;15:274-6. [DOI: 10.1111/j.1365-3156.2009.02462.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
42 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. [PMID: 20091503 DOI: 10.1002/14651858.cd000171.pub3] [Cited by in Crossref: 128] [Cited by in F6Publishing: 280] [Article Influence: 9.8] [Reference Citation Analysis]
43 Lawn SD, Wood R. Tuberculosis in HIV. Infectious Diseases 2010. [DOI: 10.1016/b978-0-323-04579-7.00093-9] [Reference Citation Analysis]
44 Glaziou P, Floyd K, Raviglione M. Global Burden and Epidemiology of Tuberculosis. Clinics in Chest Medicine 2009;30:621-36. [DOI: 10.1016/j.ccm.2009.08.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
45 Marais BJ, Ayles H, Graham SM, Godfrey-faussett P. Screening and Preventive Therapy for Tuberculosis. Clinics in Chest Medicine 2009;30:827-46. [DOI: 10.1016/j.ccm.2009.08.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
46 Basu S, Stuckler D, Gonsalves G, Lurie M. The production of consumption: addressing the impact of mineral mining on tuberculosis in southern Africa. Global Health 2009;5:11. [PMID: 19785769 DOI: 10.1186/1744-8603-5-11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
47 Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-25. [PMID: 19461502 DOI: 10.1097/QAD.0b013e32832d3b6d] [Cited by in Crossref: 224] [Cited by in F6Publishing: 246] [Article Influence: 16.0] [Reference Citation Analysis]
48 Richeldi L, Losi M, D'amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM. Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients. Chest 2009;136:198-204. [DOI: 10.1378/chest.08-2575] [Cited by in Crossref: 107] [Cited by in F6Publishing: 112] [Article Influence: 7.6] [Reference Citation Analysis]
49 Virchow JC. [Prevention of respiratory tract diseases]. Internist (Berl) 2008;49:170-7. [PMID: 18210024 DOI: 10.1007/s00108-007-1997-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Pathak AK, Pathak V, Suling WJ, Riordan JR, Gurcha SS, Besra GS, Reynolds RC. Synthesis of deoxygenated alpha(1-->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis. Bioorg Med Chem 2009;17:872-81. [PMID: 19056279 DOI: 10.1016/j.bmc.2008.11.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
51 Grossman C, Kushinka J, Brath LK. A 41-year-old woman with AIDS, mediastinal lymphadenopathy, and fever of unknown origin. Am J Med Sci 2008;336:349-52. [PMID: 18854679 DOI: 10.1097/MAJ.0b013e318167b0e4] [Reference Citation Analysis]
52 Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22:1897-908. [PMID: 18784453 DOI: 10.1097/QAD.0b013e32830007cd] [Cited by in Crossref: 450] [Cited by in F6Publishing: 505] [Article Influence: 30.0] [Reference Citation Analysis]
53 Wallrauch C, Bärnighausen T, Heller T, Houlihan C, Newell M. The white and the three-letter plague: integration of TB and HIV care in sub-Saharan Africa. Future HIV Therapy 2008;2:437-451. [DOI: 10.2217/17469600.2.5.437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
54 Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 2007;196 Suppl 1:S1-3. [PMID: 17624818 DOI: 10.1086/518667] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]